Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25 per share offer to buy Aerie Pharmaceuticals in a transaction that values the U
The European Commission has approved Oncopeptides' Pepaxti in combination with dexamethasone for multiple myeloma patients with so-called triple class refractory disease – in other words th
Endo International is the latest drugmaker to file for chapter 11 bankruptcy protection in connection with opioid litigation in the US, after agreeing a $6 billion deal with creditors that
The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma compa
AstraZeneca and Merck & Co's PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its use broadened if a new marke
On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to the drug in Asia held by Chinese drugmaker Everest Medic
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.